0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters |

No Effect on SOD1 Splicing by TARDP or FUS Mutations FREE

Véronique V. Belzil, MSc; Hussein Daoud, PhD; Patrick A. Dion, PhD; Guy A. Rouleau, MD, PhD
[+] Author Affiliations

Author Affiliations: Research Center, Centre of Excellence in Neuromics of Université de Montréal Centre Hospitalier de l’Université de Montréal (CHUM) (Ms Belzil and Drs Daoud, Dion, and Rouleau); Departments of Pathology and Cellular Biology (Dr Dion) and Medicine, Faculty of Medicine (Dr Rouleau), Université de Montreal; and the Research Center, Centre Hospitalier Universitaire Sainte-Justine (Dr Rouleau), Montreal, Quebec, Canada.


Arch Neurol. 2011;68(3):395-399. doi:10.1001/archneurol.2011.1.
Text Size: A A A
Published online

Amyotrophic lateral sclerosis (ALS) is characterized by a neuronal loss in the motor cortex, brainstem, and spinal cord that progresses over a 3 to 5 year period. Approximately 90% of cases are considered sporadic, while the other 10% of cases are familial.1 Extensive research has been conducted on the SOD1 (RefSeq NM_000454.4) gene after mutations were identified more than 17 years ago in 15% to 20% of familial ALS cases, as well as a small number of sporadic ALS cases in later reports.1 In the last 2 years, mutations in TARDBP, which encodes TAR DNA-binding protein 43 (TDP-43), and in FUS have been identified in both familial and sporadic ALS cases.24 Both genes encode for RNA/DNA binding proteins, are mainly localized in the nucleus, and are implicated in the regulation of RNA processing.5 Specifically, TDP-43 and FUS have been shown to be associated with other splicing factors and are believed to play a role in splicing regulation, as variation in their expression level influences the splicing of certain targets.5 Interestingly, mutant TDP-43 proteins identified in patients with ALS were recently reported to be more stable than wild-type TDP-43 and to display an enhanced interaction with fused in sarcoma (FUS) polypeptides.6 Particularly, it was reported that the FUS protein interacts more predominantly with mutant TDP-43, which display an increased half-life compared with wild-type TDP-43. The authors concluded on a note about the efforts needed to determine whether the increased association affects the RNA targets for TDP-43, FUS/translocated in liposarcoma protein, or both.6 Considering that abnormal RNA processing and splicing patterns are involved in neurodegenerative diseases1 and that variation in the RNA splicing of SOD1 can cause familial ALS by destabilizing the resulting protein,1 our aim was to assess if TARDBP and/or FUS ALS-predisposing mutations that are known to lead to the accumulation of TDP-43 or FUS aggregations in the cytoplasm also lead to aberrant SOD1 RNA splicing events, and to determine if SOD1 could be an RNA target for TDP-43, FUS, or both.

We studied total RNA prepared from immortalized lymphoblastoid cells of 1 healthy control individual as well as 7 participants with different TARDBP mutations (p.D169G, p.G287S, p.G348C, p.R361S, p.Y374X, p.A382T, p.N390D) and 4 participants with different FUS mutations (p.P18S, p.G174del, c.1542-2A>C, p.R521H). Protocols were approved by the ethics committee and the institutional review board of the University of Montreal. All patients gave written informed consent, after which patient information and blood were collected. The RNA was extracted using standard conditions. Reverse-transcription polymerase chain reactions were conducted using prepared complement DNA and the Moloney murine leukemia virus reverse transcriptase enzyme (Invitrogen, Carlsbad, California) per the manufacturer's instructions. The amplifications were performed using 2 sets of primer pairs that covered the entire messenger RNA of SOD1. Polymerase chain reaction products were sequenced at the Genome Quebec Innovation Centre (Montréal, Québec, Canada) using a 3730XL DNA analyzer (Applied Biosystems, Carlsbad, California). The first set amplified a region of 423 base pairs (bp) (c.1-439), starting at the beginning of the 5′ untranslated region and ending at the beginning of exon 4. The second set of primers amplified a product of 528 bp (c.398-462), starting at the beginning of exon 4 and ending at the end of the 3′ untranslated region.

Agarose gel electrophoresis showed that only 1 product was amplified for each of the complement DNA amplified (Figure). In addition, no variation was found in the sequence traces of the SOD1 complement DNA products.

Place holder to copy figure label and caption
Figure.

Agarose gel electrophoresis of SOD1 messenger RNA. The first amplified product of 423 base pairs (bp) for the control and the 11 TARDBP or FUS mutants is shown on top. The second product of 528 bp is shown under the first product for the same samples.

Graphic Jump Location

We can conclude that TARDBP or FUS ALS-predisposing mutations do not affect the splicing of SOD1 and that, while it can't be excluded that there may be a common ALS pathogenic pathway, it appears that mutant TARDBP and FUS do not act by affecting the splicing of the most frequently mutated gene, SOD1, in ALS.

Correspondence: Dr Rouleau, CHUM Research Centre, Notre-Dame Hospital, 1560 Sherbrooke E, Y-3633, Montreal, QC H2L 4M1, Canada (guy.rouleau@umontreal.ca).

Author Contributions:Study concept and design: Belzil, Dion, and Rouleau. Acquisition of data: Daoud. Analysis and interpretation of data: Belzil, Daoud, and Dion. Drafting of the manuscript: Belzil. Critical revision of the manuscript for important intellectual content: Belzil, Daoud, Dion, and Rouleau. Obtained funding: Rouleau. Administrative, technical, and material support: Belzil, Daoud, and Dion. Study supervision: Dion and Rouleau.

Financial Disclosure: None reported.

Funding/Support: This study was supported by the Canadian Institutes of Health Research (Ms Belzil and Drs Daoud and Rouleau).

Additional Contributions: We would like to thank the patients involved in this study.

Dion  PADaoud  HRouleau  GA Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nat Rev Genet 2009;10 (11) 769- 782
PubMed Link to Article
Kabashi  EValdmanis  PNDion  P  et al.  TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008;40 (5) 572- 574
PubMed Link to Article
Kwiatkowski  TJ  JrBosco  DALeclerc  AL  et al.  Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323 (5918) 1205- 1208
PubMed Link to Article
Belzil  VVValdmanis  PNDion  PA  et al. S2D team, Mutations in FUS cause FALS and SALS in French and French Canadian populations. Neurology 2009;73 (15) 1176- 1179
PubMed Link to Article
Lagier-Tourenne  CPolymenidou  MCleveland  DW TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet 2010;19 (R1) R46- R64
PubMed Link to Article
Ling  SCAlbuquerque  CPHan  JS  et al.  ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci U S A 2010;107 (30) 13318- 13323
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure.

Agarose gel electrophoresis of SOD1 messenger RNA. The first amplified product of 423 base pairs (bp) for the control and the 11 TARDBP or FUS mutants is shown on top. The second product of 528 bp is shown under the first product for the same samples.

Graphic Jump Location

Tables

References

Dion  PADaoud  HRouleau  GA Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nat Rev Genet 2009;10 (11) 769- 782
PubMed Link to Article
Kabashi  EValdmanis  PNDion  P  et al.  TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008;40 (5) 572- 574
PubMed Link to Article
Kwiatkowski  TJ  JrBosco  DALeclerc  AL  et al.  Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323 (5918) 1205- 1208
PubMed Link to Article
Belzil  VVValdmanis  PNDion  PA  et al. S2D team, Mutations in FUS cause FALS and SALS in French and French Canadian populations. Neurology 2009;73 (15) 1176- 1179
PubMed Link to Article
Lagier-Tourenne  CPolymenidou  MCleveland  DW TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet 2010;19 (R1) R46- R64
PubMed Link to Article
Ling  SCAlbuquerque  CPHan  JS  et al.  ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci U S A 2010;107 (30) 13318- 13323
PubMed Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles